Quarterly report pursuant to Section 13 or 15(d)

Description of Business and Basis of Presentation - Additional Information (Detail)

v3.23.2
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Basis Of Presentation [Line Items]            
Common Stock, Shares, Issued 1,019   1,019   77  
Proceeds from the sale of common stock     $ 8,502 $ 5,849    
Net loss $ (4,868) $ (5,611) (10,717) (10,386)    
capital expenditures     $ 900      
Common stock, par value $ 0.001   $ 0.001   $ 0.001  
Gross proceeds from warrant exercises     $ 600      
Prepaid expenses and other current assets $ 2,170   2,170   $ 3,053  
Working capital 9,800   9,800   11,200  
Cash and cash equivalents 6,930   6,930   4,181  
Cash, cash equivalents, and restricted cash 6,930 $ 19,549 6,930 19,549 4,181 $ 30,175
Net cash and cash equivalents used in investing activities     (944) (578)    
Accounts receivable, net $ 5,717   5,717   $ 5,841  
Net cash used in operating activities     $ (9,220) $ (14,633)    
Reverse stock split     At a special meeting of BIOLASE stockholders held on July 20, 2023 (the "special meeting"), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of BIOLASE common stock, at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, the Board approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of BIOLASE common stock (the “2023 Reverse Stock Split”).      
January 2023 Public Offering [Member]            
Basis Of Presentation [Line Items]            
Proceeds from the sale of common stock     $ 8,500      
May 2023 Public Offering [Member]            
Basis Of Presentation [Line Items]            
Proceeds from the sale of common stock     $ 3,700      
BIOLASE stockholders [Member]            
Basis Of Presentation [Line Items]            
Reverse Stock Split     a reverse stock split of BIOLASE common stock, at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors (the "Board") approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of BIOLASE common stock (the “2023 Reverse Stock Split”)